Abstract
Importance Peripartum depression (PeriPD) is a prevalent condition with serious, long-term consequences for mother and child. Emotion regulation (ER) is increasingly recognized as key factor for maternal mental health and parenting. However, evidence remains limited regarding the relation of ER difficulties and depressive symptoms across the peripartum.
Objective To determine whether self-reported ER difficulties in the antepartum are associated with depressive symptoms at multiple peripartum timepoints. Secondary: Whether PeriPD trajectories differ on antepartum ER difficulties.
Design, Setting and Participants Data for this study were collected from January 2022 to April 2024 through the Mom2B cohort, a population-based, prospective Swedish national study using a smartphone app for data collection. The cohort includes Swedish-speaking, pregnant women over 18 years, residing in Sweden, who downloaded the Mom2B app. Eligibility for this sub-study required verification of pregnancy and delivery, along with complete background information (N = 1414). Participants were included if they completed the Difficulties in Emotion Regulation Scale-16 (DERS-16) during the second trimester (N = 623).
Exposure DERS-16 total score at 16-25 weeks antepartum.
Outcomes and Measures Depressive symptoms were assessed using the Edinburgh Postnatal Depression Scale (EPDS) at seven timepoints: 24-34, 36-42 weeks antepartum, and 1-4, 6-13, 14-23, 24-35, 36-42 weeks postpartum. Multiple linear regression models examined DERS-16 scores as exposure, with EPDS scores as outcomes, adjusting for potential confounders. Secondary: Comparison of DERS-16 scores between PeriPD trajectories using ANOVA.
Results 623 pregnant women, aged 19-44, were included. DERS-16 scores were strongly associated with EPDS scores up to 14-23 weeks postpartum, even after adjusting for potential confounders (all regression coefficients = .06 - .23, all 95% CIs = .00 - .26, all p-values < .05). Secondary: 134 participants were classified into a specific PeriPD trajectory. DERS-16 scores differed between trajectories (F(4,129) = 26.68, p < .001, ηp2 = .45), with higher ER difficulties in early and late postpartum-onset trajectories compared to the healthy group (p = .017 and p = .018, respectively).
Conclusion and Relevance ER difficulties in the second trimester present a robust vulnerability marker for PeriPD symptoms, particularly for progression to postpartum depression. The DERS-16 may aid in early detection of peripartum mental health risks, while enhancing ER offers a promising intervention approach. Further research is needed to evaluate DERS-16’s clinical utility and optimize ER-centered interventions for at-risk trajectories.
Keypoints
Question. Are self-reported difficulties in emotion regulation (ER) in the second trimester of pregnancy associated with depressive symptoms at multiple peripartum timepoints?
Findings. In this population-based prospective Swedish national cohort study, difficulties in ER assessed in the second trimester were significantly associated with higher depressive symptoms during pregnancy and up to six months postpartum, even after adjusting for potential confounders.
Meaning. The study’s findings suggest that ER difficulties during pregnancy present a robust vulnerability marker for depressive symptoms across the peripartum, especially postpartum, and may provide an opportunity for early detection and intervention approaches of peripartum depression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was funded by the German Research Foundation (DFG) as part of the International Research Training Group "Women's Mental Health Across the Reproductive Years" (IRTG2804). Additionally, the Mom2B-project has received funding from the Swedish Research Council (Grant numbers 2020-01965), the Swedish Brain Foundation (Grant numbers FO2021-0161, FO2022-0098), the Swedish state under the ALF-agreement, the Olle Engkvists Foundation (224-0064), and the Swedish Association of Local Authorities and Regions (to the Department of Obstetrics and Gynaecology, Uppsala University).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the Swedish Ethical Review Committee (dnr: 2019/01170, with amendments) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
Datasets used in the present study are available upon reasonable request from the corresponding authors.
